2024, Disease and Fragment Screening

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

2024

Disease

Fragment Screening

Advancements in hit identification for membrane protein drug discovery

Drug Target Review

APRIL 7, 2025

The challenge of GPCR drug discovery G protein-coupled receptors (GPCRs) are one of the most desirable and challenging target classes in drug discovery, as their mutation can lead to a wide range of diseases such as cancer, cardiovascular disorders and neurological conditions. References Sun D, et al.

Fragment Screening

Fragment Screening Drugs Biophysical Assays Small Molecule

Covalent Fragment Screening and Optimization Identifies the Chloroacetohydrazide Scaffold as Inhibitors for Ubiquitin C-terminal Hydrolase L1

Covalent Modifiers

MARCH 19, 2024

Flaherty Journal of Medicinal Chemistry 2024 DOI: 10.1021/acs.jmedchem.3c01661 3c01661 Dysregulation of the ubiquitin-proteasome systems is a hallmark of various disease states including neurodegenerative diseases and cancer. Kessler, Michael K. Wendt, Chittaranjan Das, and Daniel P.

Fragment Screening

Fragment Screening Disease Treatment

Drug Discovery Digest

Advancements in hit identification for membrane protein drug discovery

Covalent Fragment Screening and Optimization Identifies the Chloroacetohydrazide Scaffold as Inhibitors for Ubiquitin C-terminal Hydrolase L1

Stay Connected